ClinicalTrials.gg

Program

CS5006

A development code.

Its studies are led by CStone Pharmaceuticals.

Furthest: phase 2, since Nov 10, 20261 company-led study, 1 open or runningNext primary completion: Jul 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CStone Pharmaceuticals11 open or runningphase 2since Nov 10, 2026Nov 10, 2026Jul 2029phase 2 · NCT07938814

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 10, 2026First study: phase 2 study in Advanced Solid TumorsFirst studyNCT07938814 · 310 planned · Australia, China

Ahead

  1. Jul 2029Primary completion: phase 2 study in Advanced Solid TumorsNCT07938814

TargetBeta

ITGB4 →read by rule
“A Phase I/II, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activities of CS5006, a Novel Antibody-Drug Conjugate Targeting ITGB4, in Participants With Advanced Solid Tumors”study text, by rule · the study

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07938814Advanced Solid Tumors · Australia, China2Not yet recruitingJul 2029310

How it is read

Names in the registry

  • “CS5006”, 1 entry

Codes read as this program: CS5006.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 17, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.